Merus N.V. COO Peter Silverman buys, sells shares in July 2025.

Merus N.V. (MRUS) has announced that its Chief Operating Officer and General Counsel, Peter B. Silverman, has made a transaction involving 25,000 shares of the company's stock. On July 17, 2025, Mr. Silverman purchased 25,000 shares at a price of $24.43 per share. Subsequently, he sold 25,000 shares at a price of $60 per share on the same day.

Merus N.V. (MRUS), a clinical-stage immuno-oncology company, has seen significant stock activity from its Chief Operating Officer and General Counsel, Peter B. Silverman. On July 17, 2025, Mr. Silverman executed a transaction involving 25,000 shares of the company's stock. He initially purchased 25,000 shares at a price of $24.43 per share. Subsequently, he sold 25,000 shares at a price of $60 per share on the same day.

The total value of the shares purchased by Mr. Silverman was $610,750, while the total value of the shares sold was $1,500,000. This transaction resulted in a net gain of $889,250 for Mr. Silverman.

Merus N.V. has been experiencing fluctuations in its stock price and trading volume. On Monday, July 10, 2023, the stock traded up $1.12, hitting $55.62. The company's trading volume was 694,277 shares, compared to its average volume of 732,623. Merus N.V. has a 52-week low of $33.19 and a 52-week high of $62.98. The firm's 50-day simple moving average is $50.76, and its 200-day simple moving average is $45.66. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of -13.63, and a beta of 1.00.

Institutional investors have shown interest in Merus N.V. Large investors such as Boxer Capital Management LLC, Paradigm Biocapital Advisors LP, Wellington Management Group LLP, Avoro Capital Advisors LLC, and Westfield Capital Management Co. LP have made significant changes to their positions in the company's stock. These changes reflect the company's potential for growth and the confidence institutional investors have in its future prospects.

Analysts have provided varying ratings and target prices for Merus N.V. Guggenheim reiterated a "buy" rating with a $109.00 target price, while Wells Fargo & Company decreased their target price from $91.00 to $89.00 and set an "overweight" rating. Wall Street Zen upgraded the stock from a "sell" rating to a "hold" rating, and William Blair reiterated an "outperform" rating. BMO Capital Markets set a $110.00 target price with an "outperform" rating. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating, and two have assigned a strong buy rating to the stock. The company presently has an average rating of "Buy" and an average price target of $84.64.

Merus N.V. has a diverse pipeline of bispecific antibody candidates, including Zenocutuzumab (MCLA-128), which is in phase 2 clinical trials for the treatment of metastatic breast cancer and castration-resistant prostate cancer. The company's stock activity and institutional investor interest indicate a level of confidence in its future growth prospects.

References:
[1] https://www.marketbeat.com/instant-alerts/merus-nv-nasdaqmrus-coo-sells-92427500-in-stock-2025-07-11/